Document:

Exhibit 10.1 -- Agreement  and Fourth  Amendment to Bridge  Securities  Purchase
Agreement among Visual Edge and certain of its stockholders

                    AGREEMENT AND FOURTH AMENDMENT TO BRIDGE
               SECURITIES PURCHASE AGREEMENT AND RELATED DOCUMENTS

     THIS AGREEMENT AND FOURTH AMENDMENT TO BRIDGE SECURITIES PURCHASE AGREEMENT
AND RELATED DOCUMENTS (the "Fourth Amendment") dated as of July 13, 2000 among
VISUAL EDGE SYSTEMS, INC., a Delaware corporation (the "Company"), INFINITY
INVESTORS LIMITED ("Infinity"), SUMMIT CAPITAL LIMITED ("Summit") and GLACIER
CAPITAL LIMITED ("Glacier") (Infinity, Summit and Glacier being collectively
referred to as the "Purchasers").

                                R E C I T A L S:

               A. The Company and the Purchasers (directly or through entities
          which previously assigned their interests therein to Purchasers) have
          entered into that certain Bridge Securities Purchase Agreement dated
          as of June 13, 1997 (the "Initial Purchase Agreement"), as amended by
          that certain First Amendment to Bridge Securities Purchase Agreement
          and Related Documents (the "First Amendment") dated as of December 31,
          1997, as further amended by that certain Agreement and Second
          Amendment to Bridge Securities Purchase Agreement and Related
          Documents (the "Second Amendment") dated as of March 27, 1998, and as
          further amended by that certain Third Amendment to Securities Purchase
          Agreement and Related Documents (the "Third Amendment") dated as of
          December 29, 1998 (collectively, the Initial Purchase Agreement, as
          amended by the First Amendment, the Second Amendment and the Third
          Amendment, being referred to herein as the "Purchase Agreement").

               B. The Convertible Notes (as defined below) matured on June 13,
          2000 and are due and payable in full by the Company to the Purchasers.

               C. The Purchasers have loaned to the Company an aggregate of
          $180,000 since January 1, 2000, which loans are now due and payable in
          full (collectively, the "$180,000 Loan").

               D. The Company is in need of additional capital and is seeking to
          consummate a financing transaction through a sale of the Company's
          securities in an amount which will provide at least $4 million of net
          proceeds to the Company (a "Financing Transaction"). The Company has
          determined that consummation of any such Financing Transaction on
          terms favorable to the Company and its stockholders will require the
          Purchasers to convert their Convertible Instruments (as defined below)
          into shares of common stock of the Company (the "Common Stock")
          contemporaneous with or immediately preceding consummation thereof. In
          addition, the Company has requested that the Purchasers provide
          certain bridge financing while the Company continues its efforts to
          consummate such Financing

<PAGE>

          Transaction. Further, in order to provide certainty as to the
          Company's capital structure while the Company attempts to consummate a
          Financing Transaction, the Company desires to amend the Conversion
          Price (as defined below) of the Convertible Instruments to provide a
          fixed Conversion Price rather than the current Conversion Price of
          77.5% of the average market price over a trading range of the
          Company's Common Stock, such amendment to be effective upon the
          satisfaction of each of the Conditions Precedent (as defined below)
          specified herein.

               E. Consistent with the foregoing Recitals, the Company has
          requested that the Purchasers (i) loan to the Company an additional
          $39,000, which loan shall be due and payable in full on or before July
          31, 2000 (the "$39,000 Loan"), (ii) extend the maturity date of the
          Convertible Notes and the $180,000 Loan and forbear from exercising
          certain of their rights under the Purchase Agreement, (iii) agree to
          commit to convert, effective upon the satisfaction of each of the
          Conditions Precedent specified herein, the Convertible Instruments,
          together with all accrued interest and dividends thereon, into shares
          of Common Stock of the Company at the amended Conversion Price
          specified herein, (iv) agree to a moratorium on the conversion of the
          Convertible Instruments on the terms specified herein and (v) agree to
          a moratorium on the exercise of their demand registration rights, and
          to waive compliance by the Company with certain provisions, under the
          Registration Rights Agreement dated June 13, 1997.

               F. The Purchasers are willing to agree with the Company's
          requests on the terms specified herein.

     NOW, THEREFORE, in consideration of the premises herein contained and other
good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

                                    ARTICLE I

                                   Definitions

     Section 1.1 Definitions. Capitalized terms used in this Fourth Amendment,
to the extent not otherwise defined herein, shall have the same meanings as in
the Purchase Agreement. In addition:

     (a)  "Conversion Price" shall mean the price at which the Convertible
          Instruments shall be converted into Common Stock.

     (b)  "Convertible Instruments" shall mean collectively the Convertible
          Notes and the Preferred Stock, as such terms are defined in the
          Purchase Agreement.

                                   ARTICLE II

                            Agreements of the Parties

     Section 2.1 Conversion Price. The Company and the Purchasers hereby agree
that the Conversion Price shall, upon satisfaction of the Conditions Precedent
set forth in Article 3 hereof, be amended to be twenty five cents ($.25) per
share of Common Stock, such that each dollar value of the Convertible
Instruments (which, for purposes of the Preferred Stock, shall be calculated as
the

                                       2

<PAGE>

Liquidation Preference thereof multiplied by the number of shares of Preferred
Stock converted) shall be convertible into four (4) shares of Common Stock.
Until the Conditions Precedent set forth in Article 3 have been satisfied, the
Conversion Price shall remain unaltered as set forth in the Purchase Agreement.

     Section 2.2 Adjustment for Reverse Stock Split. The Conversion Price shall
be adjusted upon the occurrence of the Reverse Stock Split (as defined below).
By way of illustration, if the Reverse Stock Split is 1 for 6, the Conversion
Price shall be adjusted from twenty five cents ($.25) per share to one dollar
and fifty cents ($1.50) per share of Common Stock.

     Section 2.3 Extension of Maturity Dates. The Company and the Purchasers
hereby agree that the maturity date of the Convertible Notes shall be extended
until July 31, 2000, and the maturity date of the $180,000 Loan shall be
extended until the earlier to occur of the Closing Date (as defined below) or
July 31, 2000.

     Section 2.4 $39,000 Loan. Infinity hereby agrees to make the $39,000 Loan
to the Company, and the Company hereby agrees to execute and deliver to Infinity
the Promissory Note in the form attached hereto as Exhibit A evidencing the
$39,000 Loan. The Company acknowledges and agrees that the $180,000 Loan and the
$39,000 Loan are each secured by all of the collateral and security interests
granted to the Purchasers by the Company and its subsidiaries applicable to the
Convertible Notes as contemplated by the Purchase Agreement.

     Section 2.5 Conversion of Convertible Instruments. The Purchasers hereby
covenant and agree that upon satisfaction of each Condition Precedent or the
waiver thereof by the Purchasers, each Purchaser shall convert all of its
respective Convertible Instruments (including all accrued and unpaid interest
and dividends payable thereon) into Common Stock (the "Conversion Shares") at
the Conversion Price of twenty five cents ($.25) per share (before giving effect
to the Reverse Stock Split). The total number of Conversion Shares to be issued
to the Purchasers, assuming the Closing Date is July 31, 2000, would be as
follows:

<TABLE>
<CAPTION>
          ============================================ ================ ============== =============
                                                         Infinity          Catalyst       Glacier
          -------------------------------------------- ---------------- -------------- -------------
          <S>                                          <C>               <C>              <C>
          Liquidation  Preference of Preferred  Stock
          (4,373  shares in the  aggregate  remaining
          outstanding)                                 $2,773,000          800,000          800,000
          -------------------------------------------- ---------------- -------------- -------------
          Principal of Convertible Notes               $1,100,000          200,000          200,000
          -------------------------------------------- ---------------- -------------- -------------
          Accrued Interest  (calculated  through July
          31, 2000)                                    $  261,800           47,600           47,600
          -------------------------------------------- ---------------- -------------- -------------
          Accrued Dividends  (calculated through July
          31, 2000)                                    $  291,165           84,000           84,000
          -------------------------------------------- ---------------- -------------- -------------
          Total Conversion Amount                      $4,425,965        1,131,600        1,131,600
          -------------------------------------------- ---------------- -------------- -------------
          Total  Conversion   Shares  Issued  (before
          giving effect to the Reverse Stock Split)    17,703,860        4,526,400        4,526,400
          ============================================ ================ ============== =============
</TABLE>

     Section 2.6 Moratorium on Conversion and Foreclosure. The Purchasers hereby
covenant and agree to refrain from converting their respective Convertible
Instruments into shares of Common Stock or exercising any other remedies as a
lender and secured party available to them under the Purchase Agreement, the
Security Agreement or any other Financing Document until the earlier to occur of
(i) August 9, 2000 or (ii) satisfaction of each Condition Precedent set forth in
Article 3 (a "Moratorium"); provided however, that should a Sale Event occur
after the date hereof

                                       3

<PAGE>

and prior to the earlier to occur of these events, then the Moratorium shall not
apply and the Purchasers shall, at their sole option, be authorized to convert
their respective Convertible Instruments into shares of Common Stock in
connection with the consummation of the Sale Event.

                                   ARTICLE III

                              Conditions Precedent

     The amendment to the Conversion Price as set forth in Section 2.1 of this
Fourth Amendment, and the agreement of the Purchasers to convert their
Convertible Instruments into shares of Common Stock at such amended Conversion
Price as set forth in Section 2.5 of this Fourth Amendment are each subject to
the conditions precedent (the date of satisfaction of such events being referred
to as the "Closing Date") (the "Conditions Precedent") that on or before the
Closing Date the Purchasers shall have received all of the following in form and
substance acceptable to it and its counsel (each or any of which Conditions
Precedent may be waived by the Purchasers in their sole and absolute
discretion):

     (a)  Evidence of the consummation by the Company of a reverse stock split
          (the "Reverse Stock Split") of at least one for four, on terms
          acceptable to the Company and each of the Purchasers, in their sole
          and absolute discretion;

     (b)  Evidence of the filing of an amendment to the Company's charter
          (following stockholder approval, if required) to reflect (i) the
          Reverse Stock Split, (ii) the amendment of the Conversion Price
          contemplated herein, and (iii) any other items required to effect the
          transactions contemplated to occur on the Closing Date.

     (c)  Evidence of the clarification of the terms of the Convertible
          Instruments if necessary and consistent with the terms of the Third
          Amendment, to provide that the Purchasers may convert accrued and
          unpaid interest and dividends thereon into shares of Common Stock at
          the Conversion Price;

     (d)  Evidence of the consummation of a Financing Transaction on terms
          satisfactory to the Company and each of the Purchasers, in their sole
          and absolute discretion;

     (e)  Consummation of the sale by Infinity of its Conversion Shares (and all
          other shares of Common Stock owned by Infinity) to Entertainment
          Education Enterprises Corporation (or its designee) on terms
          acceptable to each of Infinity and Entertainment Education Enterprises
          Corporation, in their sole and absolute discretion;

     (f)  Evidence of the engagement by the Company of Pierre Koshakji and
          Johann Schotte as officers of the Company on terms acceptable to each
          of the Purchasers, the Company and Messrs. Koshakji and Schotte;

     (g)  Payment in full of the $39,000 Loan by the Company;

     (h)  Either payment in full of the $180,000 Loan by the Company or the
          restructuring of the terms of the $180,000 Loan on terms acceptable to
          the Company and the Purchasers, in their sole and absolute discretion;

                                       4

<PAGE>

     (i)  Evidence of the consummation of an investment by the Company in
          Hencie.com, Inc. in exchange for an equity interest therein on terms
          acceptable to the Purchasers and the Company, in their sole and
          absolute discretion; and

     (j)  Payment to the Purchasers by the Company of the fees and expenses of
          its counsel pursuant to Section 5.9 hereof.

                                   ARTICLE IV

          Ratification; Representations and Warranties; Acknowledgments

     Section 4.1 Ratification. The terms and provisions of the Financing
Documents, as modified by this Fourth Amendment, are ratified and confirmed and
shall continue in full force and effect. The Company acknowledges and agrees
that each of the Financing Documents, as amended hereby, is and shall remain in
full force and effect and is and shall continue to be the legal, valid and
binding obligation of the Company, enforceable against it in accordance with
their respective terms. The Company further acknowledges and agrees that the
Promissory Notes evidencing the $180,000 Loan and the $39,000 Loan are each
Financing Documents, as contemplated by the Purchase Agreement.

     Section 4.2 Representations and Warranties. The Company hereby represents
and warrants to the Purchasers that: (a) the execution, delivery and performance
of this Fourth Amendment and all other transactions and documents contemplated
hereby have been authorized by all requisite corporate action on the part of the
Company; (b) this Fourth Amendment constitutes a legal, valid and binding
obligation of the Company, enforceable against the Company in accordance with
its terms, subject to or limited by liquidation, bankruptcy, conservatorship,
insolvency, reorganization, rearrangement, moratorium or other similar law
relating to or affecting the rights of creditors generally and general
principles of equity (regardless of whether such enforceability is considered in
a proceeding in equity or at law); (c) there is no provision of law, in the
charter or bylaws of the Company, and no provision of any existing mortgage,
contract, lease, indenture or agreement binding on the Company, which would be
contravened by the making or delivery of this Fourth Agreement, or by the
performance or observance of any of the terms hereof; and (d) the execution,
delivery and performance of this Fourth Agreement and the transactions
contemplated hereby do not require any approval or consent of, or filing or
registration with, any governmental or other agency or authority, of
stockholders, or of any other party, or, if such approval or consent is
required, the same has been obtained.

     Section 4.3 Representations and Warranties of Purchasers. Each of the
Purchasers hereby represents and warrants to the Company that: (a) the
execution, delivery and performance of this Fourth Amendment and all other
transactions and documents contemplated hereby have been authorized by all
requisite action on the part of such Purchaser, (b) this Fourth Amendment
constitutes a legal, valid and binding obligation of such Purchaser, enforceable
against such Purchaser in accordance with its terms, subject to or limited by
liquidation, bankruptcy, conservatorship, insolvency, reorganization,
rearrangement, moratorium or other similar law relating to or affecting the
rights of creditors generally and general principles of equity (regardless of
whether such enforceability is considered in a proceeding in equity or at law);
(c) there is no Purchaser, and no provision of any existing mortgage, contract,
lease, indenture or agreement

                                       5

<PAGE>

binding on such Purchaser, which would be contravened by the making or delivery
of this Fourth Amendment, or by the performance or observance of any of the
terms hereof; and (d) the execution, delivery and performance of this Fourth
Amendment and the transactions contemplated hereby do not require any approval
or consent of, or filing or registration with, any governmental or other agency
or authority, of stockholders, or of any other party, or, if such approval or
consent is required, the same has been obtained.

     Section 4.4 Acknowledgments by the Company. The Company hereby acknowledges
that (a) Arter & Hadden LLP has acted as counsel solely for the Purchasers in
connection with the negotiation and preparation of this Fourth Amendment and
that the Company has been represented by its independent counsel with respect to
such matters and (b) John Wagner and Keith Benedict, directors of the Company,
have, in such capacity, abstained from any involvement in the discussions,
deliberations and voting in any way relating to the approval by the Company of
this Fourth Amendment.

     Section 4.5 Registration Rights. The Registrable Securities defined in the
Registration Rights Agreement dated June 13, 1997 shall be amended promptly
after the conversion contemplated by Section 2.5 to include all shares of Common
Stock now owned by the Purchasers and their assignees and all shares issuable
upon conversion of the Convertible Instruments. In addition, the Purchasers
hereby agree to forebear from exercising any demand registration rights under
the Registration Rights Agreement until December 31, 2000 and hereby waive
compliance by the Company of its obligations under Section 2.3 of such
Registration Rights Agreement until December 31, 2000.

                                    ARTICLE V

                                  Miscellaneous

     Section 5.1 Survival of Representations, Warranties and Covenants. All
representations, warranties and covenants made in this Fourth Amendment or any
other document furnished in connection with this Fourth Amendment shall survive
the execution and delivery of this Fourth Amendment, and no investigation by the
Purchasers or any closing shall affect the representations, warranties and
covenants or the right of the Purchasers to rely upon them.

     Section 5.2 References to Financing Documents. The Financing Documents and
any and all other agreements, documents or instruments now or hereafter executed
and delivered pursuant to the terms hereof or pursuant to the terms of the
Financing Documents, as amended hereby, are hereby amended so that any reference
therein to the Financing Documents shall mean a reference to the Financing
Documents as amended hereby.

     Section 5.3 Further Assurances. The Company and each Purchaser hereby agree
that at any time and from time to time, upon the written request of the other
party, it will execute and deliver such further documents and do such further
acts and things as the other party may reasonably request in order to fully
effect the purposes of this Fourth Amendment.

     Section 5.4 Severability. Any provision of this Fourth Amendment held by a
court of competent jurisdiction to be invalid or unenforceable shall not impair
or invalidate the remainder of this Fourth Amendment and the effect thereof
shall be confined to the provision so held to be invalid or unenforceable.

                                       6

<PAGE>

     Section 5.5 Applicable Law. This Fourth Amendment and all other documents
executed pursuant hereto shall be governed by and construed in accordance with
the laws of the State of New York.

     Section 5.6 Successors and Assigns. This Fourth Amendment is binding upon
and shall inure to the benefit of the Purchasers and the Company, and their
respective successors and assigns, except the Company may not assign or transfer
any of its rights or obligations hereunder without the prior written consent of
the Purchasers.

     Section 5.7 Effect of Waiver. No consent or waiver, express or implied, by
the Purchasers to or for any breach of or deviation from any covenant, condition
or duty by the Company shall be deemed a consent or waiver to or of any other
breach of the same or any other covenant, condition or duty.

     Section 5.8 ENTIRE AGREEMENT. THE PURCHASE AGREEMENT AS AMENDED HEREBY, THE
OTHER FINANCING DOCUMENTS AND ALL AGREEMENTS EXECUTED IN CONNECTION WITH THIS
FOURTH AMENDMENT REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES WITH RESPECT
TO THE SUBJECT MATTER THEREOF AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR,
CONTEMPORANEOUS OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO
UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.

     Section 5.9 Fees and Expenses. The Company agrees to pay: (a) all of its
own fees and expenses incurred in connection with this Fourth Amendment; and (b)
all fees and expenses of counsel incurred by Purchasers in connection with the
negotiation and preparation of this Fourth Amendment and each other agreement
and document contemplated by this Fourth Amendment (including, without
limitation, the agreements and documents required to satisfy each Condition
Precedent).

     Section 5.10 Headings. The headings, captions, and arrangements used in
this Fourth Amendment are for convenience only and shall not affect the
interpretation of this Fourth Amendment.

                            [Signature page follows]

                                       7

<PAGE>

     IN WITNESS WHEREOF, the parties hereto have executed and delivered this
Fourth Amendment as of the date first written above.

                                        VISUAL EDGE SYSTEMS, INC.

                                        By:   /s/ Thomas Peters
                                              ----------------------------------

                                        Name: Thomas Peters
                                              ----------------------------------

                                        Title: President
                                              ----------------------------------

                                        INFINITY INVESTORS LIMITED

                                        By:   /s/ James E. Martin
                                              ----------------------------------

                                        Name: James E. Martin
                                              ----------------------------------

                                        Title: Director
                                              ----------------------------------

                                        SUMMIT CAPITAL LIMITED

                                        By:   /s/ J.A. Loughran
                                              ----------------------------------

                                        Name: J.A. Loughran
                                              ----------------------------------

                                        Title: Director
                                              ----------------------------------

                                        GLACIER CAPITAL LIMITED

                                        By:   /s/ J.A. Loughran
                                              ----------------------------------

                                        Name: J.A. Loughran
                                              ----------------------------------

                                        Title: Director
                                              ----------------------------------

                                       8<PAGE>   1
                                                                   EXHIBIT 10.1

                         ROYALTY ACCELERATION AGREEMENT

THIS ROYALTY ACCELERATION AGREEMENT (the "AGREEMENT") made as of June 16, 2000
by and between Sunrise Technologies International, Inc., f/k/a Laser Biotech,
Inc., a Delaware corporation, having its principal place of business at 3400
West Warren Avenue, Fremont, California 94538 (hereinafter "SUNRISE") and Bruce
J. Sand, M.D., F.A.C.S. of 638 Lindero Canyon Road, Suite 507, Oak Park,
California 91301 (hereinafter "DR. SAND");

                              W I T N E S S E T H :

WHEREAS the parties to this Agreement have entered into that certain Amended and
Restated Patent and Technology Assignment Agreement dated June 16, 2000 (the
"AMENDED AND RESTATED PATENT AND TECHNOLOGY ASSIGNMENT AGREEMENT") amending that
certain Patent and Technology Assignment Agreement dated April 3, 1992, as
amended by that certain letter agreement dated November 16, 1994 (collectively,
and together with all other agreements whether oral or written between the
parties existing prior to the date hereof, the "ORIGINAL ASSIGNMENT AGREEMENT")
whereby Dr. Sand licensed to Sunrise certain patents and technologies; and

WHEREAS, Sunrise and Dr. Sand hereby agree to amend and alter all prior
arrangements between the parties regarding Dr. Sand's royalty rights under the
Original Assignment Agreement by hereby accelerating all of Dr. Sand's rights to
such royalties under the Original Assignment Agreement in exchange for warrants
of common stock in Sunrise Technologies International, Inc. to the mutual
benefit of the parties. The accelerated value is the fair market value of the
royalty Dr. Sand will receive in exchange for all of his rights under the
Original Assignment Agreement. Upon signing this Royalty Acceleration Agreement,
Dr. Sand terminates all rights to any royalties under the Original Assignment
Agreement.

NOW THEREFORE, in consideration of the mutual covenants and agreements herein
contained and for other good and valuable consideration (the receipt and
sufficiency of which are hereby acknowledged) the parties hereby covenant and
agree with each other as follows:

                             ARTICLE I: DEFINITIONS

1.1     "Product" means a laser device for the shrinking of collagen tissue,
        comprising: (i) a laser source (including power supply); and (ii) a
        device through which the laser beam is delivered to the collagen tissue;
        if Sunrise's manufacture or sale of such device would directly or
        contributorily infringe or induce infringement of a Valid Claim in the
        country for which the device is made or in which the device is sold.

1.2     "Patent Rights" means all worldwide rights of Dr. Sand to any subject
        matter described, claimed or covered by any of the patents or patent
        applications listed in Exhibit A, including any foreign counterparts,
        continuations, continuations-in-part, divisions, and reissues, and
        extensions of any of the foregoing.

                                       1
<PAGE>   2

1.3     "Related Technology" means all ideas, know-how, trade secrets, data,
        inventions, discoveries and any other proprietary rights (excluding the
        Patent Rights) related to the Patent Rights developed in whole or in
        part by Dr. Sand prior to or during the term of this Agreement.

1.4     "Valid Claim" means a claim of an issued and unexpired patent included
        within the Patent Rights that has not been held unenforceable,
        unpatentable or invalid by a decision of a court or governmental agency
        of competent jurisdiction, and that has not been admitted to be invalid
        or unenforceable through reissue disclaimer or otherwise.

                       ARTICLE 2: ACCELERATION OF ROYALTY
                         RIGHTS IN EXCHANGE OF WARRANTS

2.1     Subject to the terms of the Royalty Acceleration Agreement, Sunrise and
        Dr. Sand hereby agree to terminate the payment of all royalties to Dr.
        Sand on sales of Products and Combination Products as provided for in
        the Original Assignment Agreement in exchange for a warrant (the
        "Warrant") to purchase 750,000 shares of common stock of Sunrise, with
        an exercise price of $.01 per share, which shall be substantially in the
        form of Exhibit B attached hereto. The receipt of such Warrant is the
        agreed present value of the future royalty stream Dr. Sand is entitled
        to receive for his transfer of all rights to the patents listed on
        Exhibit A. Dr. Sand shall assign the patent titled "Prevention of
        Regression in Refractive Keratoplasty" application #09\550,579. In
        addition, Edward King shall receive a warrant to purchase 67,500 shares
        of common stock of Sunrise, with an exercise price of $.01 per share,
        which shall be in the form of Exhibit C attached hereto.

2.2     Dr. Sand hereby agrees (i) to accept the Warrant in exchange for the
        termination of all of his royalty rights on the sales of Products and
        Combination Products as provided for in the Original Assignment
        Agreements and (ii) to assign to Sunrise free of all liens and claims
        all the patent and technologies contemplated in the Amended and Restated
        Patent and Technology Assignment Agreement including, but not limited
        to, the patent titled "Prevention of Regression in Refractive
        Keratoplasty" application #09\550,579.

                         ARTICLE 3: TERM AND TERMINATION

3.1     Unless sooner terminated pursuant to this Article 3, this Agreement
        shall commence upon the date hereof and shall automatically expire upon
        the later of (a) the expiration of the last-to-expire patent within the
        Patent Rights, or (b) the abandonment of the last application within the
        Patent Rights.

        All of the provisions of this Agreement shall survive expiration of this
        Agreement except Article 2, which shall terminate.

3.2     GENERAL. Upon the expiration or termination of this Agreement for any
        reason, nothing herein shall be construed to release either party from
        any obligation that matured prior to the effective date of such
        termination.

                                       2
<PAGE>   3

                           ARTICLE 4: CONFIDENTIALITY

4.1     OBLIGATIONS OF DR. SAND. All scientific and technical information known
        or possessed by Dr. Sand concerning the Patent Rights or the Related
        Technology shall be deemed "Confidential Information." Dr. Sand shall
        not disclose or provide any such Confidential Information to any third
        party without the other party's prior written consent.

4.2     OBLIGATIONS OF SUNRISE. Sunrise shall protect the Confidential
        Information in a manner consistent with Sunrise's protection of its
        other confidential information.

                    ARTICLE 5: REPRESENTATIONS AND WARRANTIES

5.1     Dr. Sand hereby acknowledges and reaffirms the representations and
        warranties set forth in Section 6.1 of Article 6 of the Amended and
        Restated Patent and Technology Assignment Agreement and such
        representations and warranties are hereby incorporated into this
        Agreement by reference.

5.2     Sunrise hereby acknowledges and reaffirms the representations and
        warranties set forth in Section 6.2 of Article 6 of the Amended and
        Restated Patent and Technology Assignment Agreement and such
        representations and warranties are hereby incorporated into this
        Agreement by reference.

                                ARTICLE 6: NOTICE

6.1     NOTICES: Any notice, request, demand or other communication by the terms
        hereof required or permitted to be given by one party to another shall
        be given in writing by registered mail, postage prepaid, addressed to
        such other party or delivered to such other party as follows:

        Sunrise:   Sunrise Technologies International, Inc.
                   3400 West Warren Avenue
                   Fremont, California 94538
                   Attn:   John Hendrick
                           Senior VP, COO
                   Phone   510.771.2307
                   Fax     510.623.9163 (fax)
                   e-Mail  jhendrick@sunrise-tech.com

        with copy to: Duane, Morris & Heckscher LLP
                      227 W. Monroe Street
                      Suite 3400
                      Chicago, Illinois 60606
                      Attn:   Eric Fogel, Esq.
                      E-Mail  emfogel@duanemorris.com

                                       3
<PAGE>   4

        Dr. Sand:  Bruce J. Sand, M.D., F.A.C.S.
                   638 Lindero Canyon Road
                   Suite 507
                   Oak Park, California 91301
                   Phone  818.991.2374
                   Fax    818.991.2264

        with copy to: Edward Vincent King, Jr.
                      King & Kelleher LLP
                      One Embarcadero Center
                      17th Floor
                      San Francisco, California 94111
                      Phone  415.781.2888
                      Fax    415.781.3011
                      E-Mail evking@kingandkelleher.com

        or at such other address as may be given by any one of the parties. Any
        notice required or permitted under this Agreement shall be in writing
        and shall be deemed to be given upon the date of personal delivery or
        within three (3) days of being mailed anywhere in the continental United
        States as registered mail postage prepaid and addressed to the addressee
        at his last address recorded on the records of Sunrise. Provided
        however, that during any postal interruption, the said three (3) day
        period shall not be deemed to commence running until after the
        termination of such postal interruption.

                          ARTICLE 7: GENERAL PROVISIONS

7.1     GOVERNING LAW: This Agreement shall be construed, governed, interpreted
        and applied in accordance with the laws of the State of California as if
        executed and fully performed within California, except that questions
        affecting the construction and effect of any patent shall be determined
        by the law of the country in which the patent was granted.

7.2     ENTIRE AGREEMENT: The parties hereto acknowledge that this instrument
        sets forth the entire agreement and understanding of the parties hereto
        as to the subject matter hereof, and shall not be subject to any change
        or modification except by the execution of a written instrument
        subscribed to by the parties hereto. Without limiting the foregoing, it
        is understood that the Original Assignment Agreement and all other
        agreements whether oral or written between the parties existing on the
        Restatement Effective Date are superseded by this Amended and Restated
        Patent and Technology Agreement and shall have no further force or
        effect whatsoever.

7.3     SEVERABILITY: The provisions of this Agreement are severable, and in the
        event that any provisions of this Agreement are determined to be invalid
        or unenforceable under any controlling body of law, such invalidity or
        enforceability shall not in any way affect the validity or
        enforceability of the remaining provisions hereof.

                                       4
<PAGE>   5

7.4     NO WAIVER: The failure of either party to assert a right hereunder or to
        insist upon compliance with any term or condition of this Agreement
        shall not constitute a waiver of that right or excuse a subsequent
        failure to perform any such term or condition by the other party.

7.5     NUMBER AND GENDER: All terms and words used in this Agreement regardless
        of the number and gender in which they are used shall be deemed and
        construed to include any other number, singular or plural, and any other
        gender, masculine or feminine or neuter as the context or sense of this
        Agreement or any paragraph or clause herein may require, the same as if
        such words have been fully and properly written in the appropriate
        number and gender.

                                     * * * *

                                       5
<PAGE>   6

IN WITNESS whereof the parties have duly executed this Agreement as of the date
first written above.

SUNRISE TECHNOLOGIES, INC.,                      BRUCE J. SAND, M.D.
F/K/A LASER BIOTECH, INC.

By: /s/ JOHN N. HENDRICK                         By: /s/ BRUCE J. SAND, M.D.
   ----------------------------                     ----------------------------

Name: John N. Hendrick
     --------------------------

Title: C.O.O.
      -------------------------

                                       6
<PAGE>   7

                                    EXHIBIT A

                                 Form of Warrant

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]